medigraphic.com
Medicina Universitaria

2007, Number 36

<< Back Next >>

Med Univer 2007; 9 (36)

Allogenic transplatation of hematopoietic cells from two umbilical cords

Ruiz DGJ, Mancías GC, González CML, Ojeda LY, Calderón GED, Marín LA, González LO, Gómez AD, Ruiz ACJ

Language: Spanish
References: 29
Page: 112-116
PDF size: 114.98 Kb.


ABSTRACT

Background: Umbilical cord blood cell transplantation is employed more frequently in the treatment of patients with hematologic malignancies. The number of hematopoietic cells in the cord limits its use and, as a result, stem cells from more than one cord are now being allografted.
Objective: To determine the viability of transplantation of hematopoietic cells form the umbilical cord of two donors.
Patients and method: We allografted five individuals, four of them with advanced hematologic diseases, with placental blood derived from two different cords in each case, using the “Mexican method” of non-ablative conditioning. Patient’s age went from 5 to 40 years. A total of 0.7 to 4.7 x 106 (median 2.02 x 106) CD34 cells from the two cords were grafted to each patient.
Results: Median time to reach above the 0.5 x 109/L granulocytes was 24 days, whereas median time to recover above 20 x 109/L platelets was 31 days. In 4 patients the graft did not take and in two patients mixed chimerism (40 and 70%) was shown after the allograf. In both instances the adoptive hematopoiesis was derived from only one of the two allografted cords. Three patients died, one of them as a result of graft versus host disease. The global survival rate at three months was 40% and the median survival rate was 37 days. These are the first five patients allografted with two cords in México.


REFERENCES

  1. Mancias-Guerra C, Ruiz-Delgado GJ, Manzano C, Diaz-Hernandez MA, et al. Umbilical cord blood transplantation using non-myeloablative conditioning: The Mexican experience. Hematology 2006;11:355-9.

  2. Chen BJ, Cui X, Sempowski GD, Domen J, Chao NJ. Hematopoietic stem cell dose correlates with the speed of immune reconstitution after stem cell transplantation. Blood 2004;103:4344-52.

  3. González-Llano O, Cárdenas-Serna JM, Rangel-Fuentes M, Mancías-Guerra C, y col. El trasplante de precursores hematopoyéticos de la sangre del cordón umbilical en un niño con leucemia linfoblástica. Medicina Univ 2002;4:181-4.

  4. Ruiz-Argüelles GJ, Gómez-Rangel D, Sánchez-Anzaldo J, Ruiz-Argüelles A, y col. Trasplante de células de cordón umbilical: informe de dos casos. Medicina Univ 2002;4:233-5.

  5. Ruiz-Argüelles GJ, Reyes-Núñez V, Garcés-Eisele J, Warwick RM, et al. Acquired hemoglobin S trait in an adult patient with secondary acute myelogenous leukemia allografted with matched unrelated umbilical cord blood cells using a non-ablative conditioning regimen. Haema 2005;8:492-6.

  6. Ruiz-Argüelles GJ, Gómez-Almaguer D, Morales-Toquero A, Gutiérrez-Aguirre CH, et al. (Latin American Cooperative Oncohematology Group). The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study. Bone Marrow Transplant 2005;36:1043-7.

  7. Kurtzberg J, Laughlin M, Graham ML, Smith C, et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996;335:157-66.

  8. Gluckman E, Rocha V, Boyer-Chammard A. Outcome of cordblood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med 1997;337:373-81.

  9. Rubinstein P, Carrier C, Scaradavou A, Kurtzberg J, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998;339:1565-77.

  10. Rubinstein P, Stevens CE. Placental blood for bone marrow replacement: the New York Blood Center’s program and clinical results. Baillieres Best Pract Res Clin Haematol 2000;13:565-84.

  11. Wagner JE, Barker JN, DeFor TE, Baker S, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002;100:1611-8.

  12. Barker JN, Krepski TP, DeFor TE, Davies SM, et al. Searching for unrelated donor hematopoietic stem cells: availability and speed of umbilical cord blood versus bone marrow. Biol Blood Marrow Transplant 2002;8:257-60.

  13. Rocha V, Cornish J, Sievers EL, Filipovich, et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001;97:2962-71.

  14. Barker JN, Davies SM, DeFor T, Ramsay NK, et al. Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis. Blood 2001;97:2957-61.

  15. Laughlin MJ, Barker J, Bambach B, Koc ON, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 2001;344:1815-22.

  16. Mathe G, Amiel JL, Schwarzenberg L, Schneider M, et al. Bone marrow transplantation in man. Transplant Proc 1969; 1(1):16-24.

  17. Zanjani E, Almeida-Porada G, Hangoc G, Broxmeyer HE. Enhanced short term engraftment of human cells in sheep transplanted with multiple cord bloods: implications for transplantation of adults. Blood 2000;96:552a.

  18. Kim DW, Chung YJ, Kim TG, Kim YL, Oh IH. Cotransplantation of third-partymesenchymal stromal cells can alleviate singledonor predominance and increase engraftment from double cord transplantation. Blood 2004;103:1941-8.

  19. Chen BJ, Cui X, Chao NJ. Addition of a second, different allogeneic graft accelerates white cell and platelet engraftment after T-cell-depleted bone marrow transplantation. Blood 2002;99:2235-40.

  20. Ende M, Ende N. Hematopoietic transplantation by means of fetal (cord) blood. Virginia Med J 1972;99:276-80.

  21. Shen BJ, Hou HS, Zhang HQ, Sui XW. Unrelated, HLA-mismatched multiple human umbilical cord blood transfusion in four cases with advanced solid tumors: initial studies. Blood Cells 1994;20:285-92.

  22. Weinreb S, Delgado J, Clavijo O, Yunis EJ, et al. Transplantation of unrelated cord blood cells. Bone Marrow Transplantation 1998;22:193-6.

  23. De Lima M, St John LS, Wieder ED. Double-chimaerism after transplantation of two human leucocyte antigen mismatched, unrelated cord blood units. Br J Haematol 2002;119:773-6.

  24. Barker DJ, Weisdorf TE, DeFor BR, Blazar PB, et al. Transplantation of two partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2004 (first edition paper, prepublished online October 5; DOI 10.1182/blood-2004-07-2717).

  25. Cornetta K, Laughlin M, Carter S. Umbilical cord blood transplantation in adults: results of a prospective, multi-institutional, NHBLI sponsored trial. Blood 2002;100:42a.

  26. Rocha V, Labopin M, Frassoni F. Results of unrelated cord blood versus unrelated bone marrow transplant in adults with acute leukemia. A matched pair analysis. Blood 2002; 100:42a.

  27. Laughlin M, Rubinstein P, Stevens C. Comparison of unrelated cord blood and unrelated bone marrow transplants for leukemia in adults: a collaborative study of the International Bone Marrow Transplant Registry and the New York Blood Center. Blood 2003;102:244a.

  28. Balen KK, Spitzer TR, Yeap BY, McAffee S, et al. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transp 2007;13:82-89.

  29. Ruiz-Argüelles GJ, Gómez-Almaguer D, Ruiz-Delgado GJ, Tarín-Arzaga LC. Ocho años de experiencia con el “método mexicano” para hacer trasplantes de células hematopoyéticas alogénicas. Gac Med Mex 2007;143:231-5.




2020     |     www.medigraphic.com